TF2 / Gilead - LARVOL DELTA

TF2- Small Cell Lung Cancer Radio Immunotherapy (clinicaltrials.gov) - P1/2; N=33; Recruiting; Sponsor: Centre René Gauducheau; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

TF2- Small Cell Lung Cancer Radio Immunotherapy (clinicaltrials.gov) - P1/2; N=33; Active, not recruiting; Sponsor: Centre René Gauducheau; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

TF2- Small Cell Lung Cancer Radio Immunotherapy (clinicaltrials.gov) - P1/2; N=18; Completed; Sponsor: Centre René Gauducheau; Active, not recruiting ➔ Completed; N=33 ➔ 18; Trial primary completion date: Jun 2017 ➔ Apr 2016

Clinical • Enrollment change • Trial completion • Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

TF2- Small Cell Lung Cancer Radio Immunotherapy (clinicaltrials.gov) - P1/2; N=33; Recruiting; Sponsor: Centre René Gauducheau; Trial primary completion date: Jun 2015 ➔ Jun 2017

Clinical • Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Immunomedics, Inc.; N=30 ➔ 0; Terminated ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Rheumatoid Arthritis • Solid Tumor

Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Recruiting ➔ Completed

Clinical • Trial completion

Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Immunomedics: Commercial Update (Immunomedics) - Anticipated patent expiry in US, Europe and Japan in 2026

Anticipated patent expiry • Oncology

iTEP-CMT: ImmunoTEP for Patients With Medullary Thyroid Carcinoma. (clinicaltrials.gov) - P1/2; N=25; Completed; Sponsor: Nantes University Hospital; Recruiting ➔ Completed

Trial completion • Biosimilar • Immunology • Oncology • Thyroid Cancer

Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Clinical • New P1 trial

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Boehringer Ingelheim; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Boehringer Ingelheim

Clinical • New P1 trial

Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of Tepotinib (clinicaltrials.gov) - P1; N=65; Completed; Sponsor: Merck KGaA, Darmstadt, Germany; Not yet recruiting ➔ Completed

Clinical • Trial completion

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Boehringer Ingelheim; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Boehringer Ingelheim

Clinical • New P1 trial